In the past two years, the medical and health industry in China has maintained a rare high growth rate. According to the "healthy China 2030 strategic plan", China's health service sector will exceed 8 trillion by 2020 and 16 trillion by 2030. "Such a fast-growing industry must be a vast blue sea." A senior investor is confident about the future of the 2017 investment world health investment summit in Shanghai.
In the face of the rapid market of health care industry, how to handle the investment opportunities in the wind? At the summit, hundreds of health service executives and investment partners launched a brainstorming session to discuss the new logic of "healthcare investment 2.0".
Over the past decade, as the policy direction of health care has changed, so has the investment style of the health industry. From the early investment in the medical equipment, to the hospital, to 2015 to focus on the new drug development, the precise medical treatment of the cluster, the gold classification diagnosis and treatment... Investment hotspots are spreading fast.
By contrast, medical investment institutions are rapidly expanding. According to the data, there were only 12 medical investment institutions in 2007, including not fully focused on healthcare. But at present, there are 216 institutions that focus on healthcare investments, and a number of comprehensive investment institutions are also looking at medical investments, with a total of about a thousand. From the fund type look, in the past, the investment medical field basically is the dollar fund mainly, now, RMB fund has become mainstream.
To sum up the development trend, in the words of xu xiaolin, chairman of hua capital capital, if the medical investment of ten years ago was called the 1.0 era, then the current medical investment has entered the 2.0 era.
Xiao-lin xu pointed out that medical investment 2.0 there are three core characteristics worthy of attention: it is more and more focuses on the r&d of enterprise innovation, research and development has become a good investment, the necessary condition to do big business, but not a sufficient condition. At present, the distribution of domestic pharmaceutical enterprises presents small, scattered and disorderly characteristics. Merger and acquisition integration must be the theme of this era. The second is that people who do industry and invest in health care will have stronger labels (more professional and more subdivided). Third, integration and development become the general trend. People who do industry will be deeply involved in the investment, and those who invest will not be able to integrate with the industry, and the future will not be sustainable.
Health industry mergers and acquisitions in 2016, according to data, case number, more than 400 mergers and acquisitions amount is more than 180 billion yuan, among them, the amount is more than 20 billion overseas m&a, whether m&a case number, involves the amount or quality of project all reached a new high. "The spring of China's health services industry is just coming." Some prominent investors have predicted that the industry will be worth more than $1 billion in 2017.
Through the data, the merger wave in the era of medical investment 2.0 also presents new features, that is, the merger and acquisition focuses on the integration of pharmaceutical enterprise varieties and channels. Huang qing, a managing partner at gait investment group, points out that for pharmaceutical companies, a good breed is the most critical resource for sustainable growth. But the new drug development cycle is long and the risk is big, so through the effective merger and acquisition can let the enterprise rely on the new variety to grow quickly. Note at the same time, mergers and acquisitions in the channel, resources, and is tied for the great product variety, namely for pharmaceutical companies, in the acquisition of products and purchase market and sales channel resources. |
